Canada’s Michael Smith Genome Sciences Centre (GSC)

Today’s Research. Tomorrow’s Medicine.

The GSC is a department of the BC Cancer Research Institute and a high-throughput genome sequencing facility. We are leaders in genomics, proteomics and bioinformatics in pursuit of novel treatment strategies for cancers and other diseases.

Among the world’s first genome centres to be established within a cancer clinic, for more than two decades our scientists and innovators have been designing and deploying cutting-edge technologies to benefit health and advance clinical research.

Among the GSC’s most significant accomplishments are the first publication to demonstrate the use of whole-genome sequencing to inform cancer treatment planning, the first published sequence of the SARS coronavirus genome and major contributions to the first physical map of the human genome as part of the Human Genome Project.

By joining the GSC you will become part of an exceptional and diverse team of scientists, clinicians, experts and professionals operating at the leading edge of clinical research. We look for people who share our core values—science, timeliness, respect—to join us on our mission to use genome science for the betterment of health and society.

Summary

Job Reference Number: PDF-01553-2021-03-08

The GSC is seeking a Post-Doctoral Fellow to conduct scientific research in the areas of immunogenomics, T cell biology, and genetically engineered cell therapy, with a special focus on discovery and characterization of therapeutic T cell receptors using novel high-throughput screening approaches.

Experience in recombinant DNA and gene editing technologies, gene therapy vectors, mammalian cell culture (including primary T cell culture), flow cytometry/FACS, and cell-based assays (such as ELISPOT) is desired. Familiarity with 2nd and 3rd generation DNA sequencing platforms (including single-cell sequencing platforms) will be an asset.

Reporting to Dr. Robert Holt, Distinguished Scientist & Co-Director of the BC Cancer Immunotherapy Program, your typical duties will include the following:
•    Contributing to the design and construction of cell libraries for high-throughput screening experiments.
•    Performing high-throughput T cell receptor profiling screens.
•    Characterization and validation of novel discoveries stemming from high-throughput screening studies. 
•    Reporting research methods and results in meetings, seminars and conferences.
•    Contributing to and/or leading scientific publications and funding proposals

Eligibility

The ideal candidate should possess a PhD degree and recent experience in immunology, genomics, cancer biology, cell biology or a related discipline. A strong publication record and track record of successful funding applications are highly desirable. This position is funded by the Michael Smith Foundation for Health Research Innovation to Commercialization program and, as such, an interest or aptitude for technology development and/or industrial applications would be a valuable asset.  

Apply

Please submit a cover letter, curriculum vitae and the names of three referees willing to provide letters of reference. The cover letter should include a brief description of your previous research experience and long-term career goals. Please email your application to bcgscjobs@bcgsc.ca.

Important!

We believe that diversity and inclusivity are essential for the advancement of human knowledge and science. We welcome all applicants and provide all employees with equal opportunity for advancement, regardless of race, colour, ancestry, place of origin, political belief, religion, marital status, family status, physical or mental disability, sex, sexual orientation, gender identity or expression, age, conviction of a criminal or summary conviction offence unrelated to their employment.

All qualified candidates are encouraged to apply; however, Canadian citizens and permanent residents will be given priority.

Due to COVID-19 restrictions, the position would require working remotely on a part-time temporary basis. This restriction would be re-evaluated upon re-contracting.

Back to top